Celebrating HUREL’s One-Year Anniversary
Today marks the one-year anniversary of Visikol acquiring the HUREL® portfolio of Micro Liver products and services. We have [...]
LC-MS/MS Quantification of the Methylation Status of Clinical Samples of NASH Liver Tissues
Nonalcoholic fatty liver disease (NAFLD) is a common hepatic disorder in individuals who drink little or no alcohol. A [...]
Visikol to present at SELECTBIO’s December 2021 Conference
Visikol's Director of Drug Discovery, Peter Worthington Ph.D., to Present at SELECTBIO's 3D-Cell Culture, Organoids, and Organs-on-Chips Conference [...]
Liver Steatosis: 2D and 3D Screening Platforms
Steatosis is characterized by abnormal retention of lipids within an organ and is most common within the liver due to [...]
PHH, HepG2 or HepaRG for Drug Induced Liver Injury Studies?
Drug-induced liver injury (DILI) is one of the most frequent causes of safety-related drug marketing withdrawal, according to the [...]
The Continuum of Liver Disease
Liver disease affects millions of people in the United States alone, resulting in tens of thousands of deaths yearly, [...]
The Surprisingly Cost-Effective Case for 3D Cell-Based Liver Models
The liver is a tantalizing organ to model because of its role in drug metabolism and as a target [...]